World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
128
Citations
68626
World Ranking
2684
National Ranking
1501

Overview

David G. Maloney is affiliated with the Fred Hutchinson Cancer Research Center in the United States. Their research primarily focuses on the field of Medicine, with a substantial number of publications addressing Oncology, Immunology, Genetics, Pathology and Forensic Medicine, and Molecular Biology.

The scientist's work heavily centers on several main topics, including:

  • CAR-T cell therapy research
  • Biosimilars and Bioanalytical Methods
  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Viral Infectious Diseases and Gene Expression in Insects
  • Virus-based gene therapy research
  • Immunotherapy and Immune Responses

David G. Maloney has contributed to multiple recent papers reflecting their focus on lymphoma and immunotherapy. Notable publications include:

  • "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study," 2020, The Lancet
  • "Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial," 2022, The Lancet
  • "Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial," 2021, The Lancet Oncology
  • "Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity," 2020, Journal of Clinical Oncology
  • "Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade," 2020, Cancer Cell

The scientist maintains frequent collaborations with other researchers in their field. Regular coauthors include Jordan Gauthier, Mazyar Shadman, Cameron J. Turtle, Alexandre V. Hirayama, and Brian G. Till.

David G. Maloney has published extensively in a range of respected venues, with many papers appearing in:

  • Blood
  • Transplantation and Cellular Therapy
  • Journal of Clinical Oncology
  • Blood Advances
  • Regular and Young Investigator Award Abstracts

Best Publications

  • Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

    Mohamed L. Sorror;Michael B. Maris;Michael B. Maris;Rainer Storb;Rainer Storb;Frederic Baron

  • IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

    David G. Maloney;Antonio J. Grillo-López;Christine A. White;David Bodkin

  • CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

    Cameron J. Turtle;Laïla Aïcha Hanafi;Carolina Berger;Theodore A. Gooley

  • Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

    Jeremy S Abramson;M Lia Palomba;Leo I Gordon;Matthew A Lunning

  • Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

    Peter A. McSweeney;Peter A. McSweeney;Peter A. McSweeney;Dietger Niederwieser;Dietger Niederwieser;Dietger Niederwieser;Judith A. Shizuru;Judith A. Shizuru;Judith A. Shizuru;Brenda M. Sandmaier;Brenda M. Sandmaier;Brenda M. Sandmaier

  • Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

    Juliane Gust;Kevin A. Hay;Kevin A. Hay;Laïla-Aïcha Hanafi;Daniel Li

  • Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

    Richard A. Miller;David G. Maloney;Roger Warnke;Ronald Levy

  • Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

    DG Maloney;TM Liles;DK Czerwinski;C Waldichuk

  • Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells

    Cameron J. Turtle;Cameron J. Turtle;Laila-Aicha Hanafi;Carolina Berger;Carolina Berger;Michael Hudecek

  • Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

    Kevin A. Hay;Kevin A. Hay;Laïla-Aïcha Hanafi;Daniel Li;Juliane Gust

  • Chimeric antigen receptor-modified T cells derived from defined CD8 + and CD4 + subsets confer superior antitumor reactivity in vivo

    Daniel Sommermeyer;Michael Hudecek;Michael Hudecek;Paula L. Kosasih;Tea Gogishvili

  • Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

    Thomas A. Davis;Antonio J. Grillo-López;Christine A. White;Peter McLaughlin

  • IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

    D G Maloney;A J Grillo-López;D J Bodkin;C A White

  • Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

    Rebecca Gardner;David Wu;Sindhu Cherian;Min Fang

  • CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

    Brian G. Till;Brian G. Till;Michael C. Jensen;Michael C. Jensen;Jinjuan Wang;Xiaojun Qian

  • Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

    Cameron J. Turtle;Kevin A. Hay;Laïla-Aïcha Hanafi;Daniel Li

  • Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases

    Dietger Niederwieser;Michael Maris;Judith A. Shizuru;Effie Petersdorf

  • Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

    Marco Mielcarek;Paul J. Martin;Wendy Leisenring;Mary E. D. Flowers

  • Hematopoietic cell transplantation (HCT)-specific-comorbidity index: A new tool for risk assessment before allogeneic HCT

    M.L. Sorror;M.B. Maris;M.B. Maris;R.F. Storb;R.F. Storb;F. Baron

  • Rituximab A nti-CD20 M onoclonal A ntibody T herapy i n Non-Hodgkin's L ymphoma: S afety a nd E fficacy o f Re-Treatment

    Thomas A. Davis;Christine A. White;Peter McLaughlin;Myron S. Czuczman

Frequent Co-Authors

Rainer Storb
Rainer Storb Fred Hutchinson Cancer Research Center
Brenda M. Sandmaier
Brenda M. Sandmaier Fred Hutchinson Cancer Research Center
Barry E. Storer
Barry E. Storer Fred Hutchinson Cancer Research Center
Oliver W. Press
Oliver W. Press University of Washington
Stanley R. Riddell
Stanley R. Riddell University of Washington
Cameron J. Turtle
Cameron J. Turtle Fred Hutchinson Cancer Research Center
Ted Gooley
Ted Gooley Fred Hutchinson Cancer Research Center
Michael A. Pulsipher
Michael A. Pulsipher University of Utah
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center
William I. Bensinger
William I. Bensinger Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in healthcare but seeking alternative or accelerated paths, there are a variety of online degree programs to consider. Many professionals opt for advanced nursing degrees, such as the shortest post master's dnp program, allowing nurses to quickly reach the highest clinical degrees available. Others may prefer options that are less intensive, such as enrolling in one of the easiest dnp programs available online, which can offer greater flexibility for working adults.

Those looking to enter the healthcare field rapidly can explore fast lpn program choices. These programs get you job-ready as a Licensed Practical Nurse in less time. For individuals passionate about mental health, the fastest psychiatric nurse practitioner program can provide a streamlined route to a specialized and in-demand career.

Exploring these online pathways can be a smart way to advance your healthcare career or transition into new medical specialties—without spending years in traditional study.

Best Scientists Citing David G. Maloney

Trending Scientists